Contineum Therapeutics, Inc. (NASDAQ: CTNM) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $31.00 price target on the stock.
Contineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)
Contineum Therapeutics Initiates Patient Dosing in Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791 [Yahoo! Finance]
Contineum Therapeutics Initiates Patient Dosing in Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791
Contineum Therapeutics to Attend the 7th Annual Evercore HealthCONx Conference